ADI-PEG20

DRUG4 trials

Sponsors

Polaris Group, Washington University School of Medicine, Chang Gung Memorial Hospital

Conditions

Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNonalcoholic Steatohepatitis (NASH)ObesityPreDiabetes

Phase 2

ADI-PEG20, Obesity and Prediabetes

WithdrawnNCT05829239

Washington University School of MedicineObesity, PreDiabetes

Start: 2024-04-01End: 2024-05-01Updated: 2024-11-07

Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

RecruitingNCT05842512

Polaris GroupNonalcoholic Steatohepatitis (NASH)

Start: 2023-09-13End: 2028-01-31Target: 60Updated: 2025-09-23

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

RecruitingNCT06034977

Chang Gung Memorial HospitalHepatocellular Carcinoma

Start: 2023-12-01End: 2026-07-23Target: 120Updated: 2023-09-13

Phase 3

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

RecruitingNCT05317819

Polaris GroupAdvanced Hepatocellular Carcinoma, Hepatocellular Carcinoma

Start: 2022-03-14End: 2028-12-31Target: 300Updated: 2025-12-18